Stories
AI Companies Run Virtual Drug Trials to Improve Human Study Success
- •Artificial intelligence startups are utilizing virtual patient simulations to predict the success or failure of experimental drugs before expensive human clinical trials begin.
- •The biopharmaceutical industry spends roughly $140 billion annually on human testing, yet only about 12% of drug candidates successfully gain regulatory approval.
- •Firms like BioinvestGPT and QuantHealth use advanced DNA sequencing, real-world data, and machine learning models to assess drug efficacy and identify clinical risks early.
- •While AI simulations are becoming increasingly accurate at forecasting trial outcomes, industry experts emphasize that human clinical trials remain necessary for final safety and approval.
Key Questions Answered
AI start-ups run simulated clinical trials to measure how virtual patients respond to experimental medicines before traditional human testing begins. These simulations aim to identify which pharmaceutical programs are worth moving forward, assess acquisition targets, and boost the odds that a drug will prove safe and effective.
Investment in artificial intelligence drug discovery more than doubled to reach $8.4 billion in 2025 compared to 2023, according to a recent report from McKinsey.
BioinvestGPT predicts failure for two Phase 3 trials of Biogen's litifilimab in lupus, as well as for Phase 2 studies of Takeda's zasocitinib in Crohn's disease and ulcerative colitis, indicating the models show both drugs are suboptimal for those trial populations.
